Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...

Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...

AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...

Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...

Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.

Roche’s Teresa Graham says patients are clamoring for breast cancer pill giredestrant as two US approval decisions near.

Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.

Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...

FDA weighs evidence standards for AI medical devices like prescription bots. AMA opposes upfront uncertainty; ATA Action supports post-market monitoring. UpDoc, AMA, and others back risk-based ...

Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.

CD­MO Adare Phar­ma So­lu­tions is clos­ing a fa­cil­i­ty in Philadel­phia and let­ting go of 137 work­ers, a lit­tle over a year af­ter re­lo­cat­ing its head­quar­ters to Penn­syl­va­nia. The ...

Deborah Waterhouse will take on the CEO post at CSL on Feb. 1 as the Australian pharma company attempts a turnaround after ...